Clinical trials: Renal Cell Cancer
Renal Cell Carcinoma, Urinary Bladder Neoplasms
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Primary objective: To assess the early signals for anti-tumor activity (i.e. objective response rate, progression-free survival) of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or…
- Trial name
- NCT02619253
- Testing
- Pembrolizumab, Vorinostat
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Nabil Adra
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer…
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03050060
- Testing
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Carcinoma, Renal Cell
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT00334282
- Testing
- Pazopanib
- Where
- 99 sites in Argentina, Australia and 23 more
- Volunteers
- 435 people
- Sponsor
- GlaxoSmithKline
Anemia, Breast Cancer
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal…
- Conditions
- Anemia, Breast Cancer, Cancer, Colorectal Cancer
- Trial name
- NCT01444456
- Where
- 117 sites in Austria, Belgium and 7 more
- Volunteers
- 1,262 people
- Sponsor
- Amgen
Metastatic Renal Cell Carcinoma
TIL Therapy for Metastatic Renal Cell Carcinoma
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma.
- Trial name
- NCT02926053
- Testing
- Surgical removal of tumor tissue for T cell production, Cyclophosphamide, Fludarabine
- Where
- Denmark
- Volunteers
- 5 people
- Sponsor
- Inge Marie Svane
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
VHL Gene Mutation, VHL
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
The primary objective of this study is to assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL participants treated with MK-3795.
- Conditions
- VHL Gene Mutation, VHL, VHL Syndrome, VHL Gene Inactivation
- Trial name
- NCT03108066
- Testing
- MK-3795
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Renal Cell Carcinoma
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Primary Objective: To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b.
- Trial name
- NCT00561912
- Testing
- Decitabine, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Genitourinary Cancer, Kidney Cancer
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug.
- Trial name
- NCT02060370
- Testing
- Sunitinib, Questionnaire
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma
Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment
The purpose of this study is to know about the quality of life of patients with metastatic renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who suffer from fatigue and hand-foot syndrome…
- Trial name
- TROYA (NCT02789137)
- Where
- 23 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Pfizer
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Cancer, Renal Cancer
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
This study will assess the immunomodulatory activity of entinostat in patients with advanced renal cell carcinoma receiving the PD-L1 inhibitor atezolizumab.
- Trial name
- NCT03024437
- Testing
- Atezolizumab, Bevacizumab, Entinostat
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Roberto Pili
Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
The trial is open to patients who have metastatic renal cell carcinoma/urothelial (bladder) carcinoma with at least 2 measurable sites of disease.
- Trial name
- NCT03115801
- Testing
- Nivolumab, Atezolizumab, Radiation & immunotherapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell
Project to Improve Communication About Serious Illness - Pilot Study
This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about…
- Conditions
- Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure
- Trial name
- PICSI-P (NCT03746392)
- Testing
- Jumpstart Intervention
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Washington
Select Advanced Malignancies, Kidney Cancer
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Participants with Select Advanced Malignancies.
- Conditions
- Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02118337
- Testing
- MEDI0680, Durvalumab, Nivolumab
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 97 people
- Sponsor
- MedImmune LLC
Transitional Cell Carcinoma of Bladder, Urethra Cancer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who…
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Trial name
- NCT01326871
- Testing
- Cisplatin, Gemcitabine, ALT-801
- Where
- 16 sites in United States
- Volunteers
- 68 people
- Sponsor
- Altor BioScience
Renal Cell Carcinoma
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
About 27,000 new cases of renal cell carcinoma (RCC) are diagnosed every year in the United States. 11,000 of these cases will die from the disease.
- Trial name
- NCT00001703
- Testing
- incomplete Freund's adjuvant, von Hippel-Lindau peptide vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Non-small Cell Lung Cancer
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma
- Trial name
- NCT03576131
- Testing
- GEN1029 (HexaBody®-DR5/DR5)
- Where
- 6 sites in United States, Spain and 1 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors.
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- IMAGINE (NCT04637594)
- Testing
- Pembrolizumab, Nivolumab, Atezolizumab
- Where
- 377 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology